Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3258 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Vertex and Tibotec initiate Phase III HCV study

The Advance trial will enroll 1,050 treatment-naive genotype 1 hepatitis C virus (HCV) patients and will evaluate two 24-week telaprevir-based regimens in comparison to a 48-week control arm.

Sciele acquires allergy injection from Verus

Under the agreement, Sciele acquired Twinject and certain other related Verus products under development for $29 million. Verus may also receive additional payments resulting from the achievement of